(1) The Directors believe the presentation of 'adjusted net loss' provides the best measure to assess the performance of the Group. Adjusted net loss excludes certain non-cash or non- recurring items. Refer to the below table for a reconciliation from reported...
Appendix 4E - Preliminary Final Report
Filed with ASX · · 20 pages · English
Release
Earlier from 4DMedical
- Azra AI and 4DMedical Partner to Bring Enterprise-Wide Lung Health Intelligence to Health Systems
- Application for quotation of securities - 4DX
- Cleansing Notice
- Update - Proposed issue of securities - 4DX
- Quarterly Activity Report and Appendix 4C
Later from 4DMedical
- FY2026 Full year results
- Notification of Date of 2026 AGM
- Ceasing to be a substantial holder
- Board transition and key personnel appointments
- Initial Director's Interest Notice - CJ
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical